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Model studies have identified 16 conserved positively
charged amino acids that form a positive strip pointing
toward the center hole of Rho. Fourteen residues were
individually changed to either an alanine or a glycine
and one to a glutamate. Residues Arg269, Arg272, Lys283,
Arg296, Lys298, and Arg299 form a subdomain (locus) lo-
cated N-terminal to (above) the ATP hydrolysis domain
(P-loop) and mutations in these residues led to either
inactive Rho or to proteins displaying decreased kcat for
poly(C)-dependent ATP hydrolysis, increased Km for
ribo(C)10 activation, and decreased transcription termi-
nation efficiencies (57–77%) compared with wild-type
Rho. Residues Arg347, Lys348, Lys352, and Arg353 form a
subdomain (locus) C-terminal to (below) the ATP hy-
drolysis domain, and mutations in these residues also
show a decreased kcat for poly(C)-dependent ATP hy-
drolysis, an increased Km for ribo(C)10 activation, and a
50–70% decrease in transcription termination, com-
pared with wild-type Rho. Residues Arg212 and Lys336
surround the ATP hydrolysis domain, and mutations in
these residues also altered the kinetic properties of Rho.
We conclude that the secondary RNA-tracking site con-
sists of amino acids whose putative orientation faces the
central hole in Rho and in part reside in two clusters of
positively charged residues located above and below the
ATP hydrolysis domain.
Rho transcription termination factor is one of several nucleic
acid-binding proteins belonging to a family of helicases with a
homohexameric structure shaped like a toroid ring that utilizes
the hydrolysis of ATP to move along the nucleic acid (1, 2). Rho
protein binds to a poorly defined cytosine-rich sequence on
nascent RNA called a rut site (Rho utilization), which contains
little or no secondary structure. Rut sites are usually found
upstream from the start of specific genes or between genes in
operons (3), and once Rho binds to the rut site, it tracks 5 to 3
toward the stalled RNA polymerase. In a poorly defined mech-
anism that may require helicase activity (4), Rho disrupts the
polymerase-transcript complex, thereby terminating transcrip-
tion. Bicyclomycin, a commercial antibiotic, has been shown to
inhibit Rho function (5) specifically by interfering with the
tracking of Rho (6). Bicyclomycin inhibits the growth of many
Gram-negative organisms, including Escherichia coli, Shigella,
and Salmonella (7) and at least one Gram-positive bacterium,
Micrococcus luteus (8), inferring the vital nature of Rho for
cellular function (9–11).
The Rho monomer consists of 419 amino acid residues di-
vided into two structural domains, a primary RNA-binding
domain (residues 1–151) and the ATP hydrolysis domain (res-
idues 167–419), which is based upon structural similarity with
F1-ATP synthase (12). The RNA-binding domain contains a
DGFGFLR (amino acid residues 60–66) conserved RPN-1 RNA
recognition motif (13, 14). A solution structure of the N-termi-
nal 130 residues of Rho has been solved using NMR techniques
(15) and a crystal structure is also available (16). The primary
RNA-binding domain sits as a cap on the toroid ring, distinct
from the ATP hydrolysis domain, and binds RNA tightly.
ATPase activity is induced by the addition of poly(C) to Rho.
Substitution of poly(dC) for poly(C) leads to tight Rho binding
but no ATP hydrolysis. The addition of short oligoribonucleo-
tides (7–10 residues long with a predominance of cytosine res-
idues) to the Rho-poly(dC) complex activates ATPase activity.
The activation by ribo(C)10 is thought to occur at the secondary
RNA-binding/tracking site (3).
Recently, the projected Q-loop region, positioned on top, in-
side the toroid ring, facing the central hole of Rho, has been
implicated in RNA binding, and this RNA-binding domain
changes conformation upon binding ATP (17). A model for Rho
tracking coupled to ATP hydrolysis that relies on the structural
similarity between Rho and the -subunit of F1-ATP synthase
and utilizes residues facing inside of the central hole in Rho has
been put forth (18). A strip of positively charged amino acids on
Rho positioned toward the inside of the hole was identified
based on the structure of bovine F1-ATP synthase (12, 19)
threaded with E. coli Rho sequence and energy minimized (18).
This model takes into account three active ATP hydrolysis sites
per hexamer, sequential hydrolysis of ATP, Rho activation by
short oligoribonucleotides, and the discrimination between hy-
drolytic and inactive subunits. The strip of positive charges was
projected to bind the polyphosphate backbone of the RNA as
Rho translocates toward the RNA polymerase. The positive
charges were clustered into two separate loci found near the N
and C termini surrounding the ATP hydrolysis domain. In this
paper, we report the effects of site mutations carried out on
these amino acid residues. We document the importance of
positive charges for Rho to hydrolyze ATP, to bind RNA, and to
terminate transcripts.
EXPERIMENTAL PROCEDURES
Materials and Enzymes—Bicyclomycin was kindly provided by Fuji-
sawa Pharmaceutical Co., Ltd. (Osaka, Japan) and was further purified
by three successive silica gel chromatographies using 20% methanol-
chloroform as the eluant (20). Oligonucleotide primers were synthesized
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by Genosys Biotechnology, Inc. (The Woodlands, TX). T4 polynucleotide
kinase, T4 DNA ligase, and restriction enzymes were purchased from
Promega Co. (Madison, WI). Pfu DNA polymerase was obtained from
Stratagene (La Jolla, CA). The metal chelating column was from Am-
ersham Biosciences.
Radionucleotides [-32P]ATP and [-32P]CTP (3000 Ci/mmol) were
purchased from PerkinElmer Life Sciences, and nucleotides and RNase
inhibitors were from Ambion, Inc. (Austin, TX). Polyethylenimine thin-
layer chromatography plates used for ATPase assays were purchased
from J. T. Baker, Inc. Ribo(C)10 was obtained from Oligos Etc. (Wilson-
ville, OR). All other chemicals were reagent grade.
Generation of Mutant Rho Sequences—The plasmid pET-RhoW that
contained wild-type rho (19) was used as a template for DNA amplifi-
cation. Overlapping primers with the desired mutation were used to
introduce base changes, as described in the QuikChangeTM site-directed
mutagenesis kit (Stratagene). The resulting PCR-amplified plasmid
DNA was digested with DpnI and transformed into host strain JM109.
Isolated plasmid DNA from the transformed cells was sequenced with
an Applied Biosystems 377 sequencer using the Big Dye reaction kit to
identify sequences with specific site changes. The entire rho gene was
sequenced to ensure that no other mutations were present in the singly
mutated gene.
Expression of Mutant Rho Proteins—One of four expression systems
were used to generate soluble and functional mutant Rho proteins: the
pET14b expression vector using host strain BL21(DE3)pLysS (T7
polymerase) (Novagen), the pET14b vector in the salt-induced T7
polymerase host BL21SI (Invitrogen), the pBAD33 vector (arabinose
induction) using host strain MG1655 (21), and the pET14b vector with
the  host HMS174 expressed by introducing T7 polymerase by trans-
fection with  phage CE6 (Novagen). For expression using host
BL21(DE3)pLysS, HSM174, or BL21SI, the original pET14b vector was
used. Expression of mutant Rho using the arabinose promoter in the
vector pBAD33 required excising the XbaI-HindIII fragment of the
pET14b vector that contained the entire rho gene including the up-
stream SD sequence but shy of the T7 promoter, and ligating it into a
similarly digested pBAD33 vector. Recombinant plasmids were trans-
formed into host MG1655, and expression was induced by adding 0.2%
arabinose to cells.
To isolate Rho, cells were centrifuged, resuspended, and lysed by the
addition of lysozyme (130 g ml1) and 0.05% deoxycholate. After brief
sonication using a Branson sonicator, the cell debris was removed by
centrifugation and the resulting supernatant was placed on a metal
chelating column (Amersham Biosciences) bound with Ni2. After
washing, the bound protein Rho was recovered using a linear gradient
of 0–0.5 M imidazole. SDS electrophoresis of the isolated Rho showed
only one peptide at 47,000 Da. Rho protein was dialyzed against storage
buffer and kept at 80 °C until used.
Poly(C)-dependent ATP Hydrolysis Assay—Poly(C)-dependent ATP
hydrolysis activity was measured as described previously (19) varying
the ATP concentrations from 9.1 to 100 M. The reactions were initiated
by adding 0.5 Ci of [-32P]ATP and varying concentrations of ATP to a
solution of 40 mM Tris-HCl, pH 7.9, 50 mM KCl, 12 mM MgCl2, 0.1 mM
EDTA, 0.1 mM dithiothreitol, 1.4 mg ml1 bovine serum albumin, 40 nM
poly(C), and Rho (33 nmol of monomer).
Poly(dC)-Ribo(C)10-dependent ATP Hydrolysis Activity—The assays
were carried out as described (6) using 200 nM Rho protein monomer.
The two different ranges of ribo(C)10 concentrations used depended
upon the Km (ribo(C)10) values. A range ribo(C)10 between 0.7 and 20 M
was used for wild-type Rho, whereas a range of ribo(C)10 between 20
and 200 M was used when the Km indicated a value much greater than
the wild-type. Estimates of Km were reported for values that exceeded
500 M because of the limited ribo(C)10 concentrations that could be
used.
Transcription Termination Assay—Transcription termination assays
were carried out using a modified trp operon (22), as described (6) with
slight modifications. In brief, the reaction was carried out in a 10-l
volume with 200 M ATP, UTP, and GTP and 20 M CTP, 7 Ci of
[-32P]CTP, 0.1 pmol of template, 0.4 units/l RNase inhibitor, 0.01
g/l E. coli RNA polymerase, and 70 nM Rho protein. Transcription
termination was measured in the absence and presence of mutant Rho
protein and in the presence of Rho plus 50 M bicyclomycin. The
transcripts were separated and visualized as described (6). Subtracting
the digitized background from both the read through and the Rho-
terminated transcripts allowed quantitation of the termination reac-
tions. The background from the wild-type Rho was subtracted from all
the mutants and the percentage of termination was calculated as the
amount of terminated transcripts divided by the amount of read
through transcript plus the amount of terminated transcript times 100.
RNA Binding Assays—Trp t RNA was made using the SalI linear-
ized pTRP5 plasmid and T7 RNA polymerase. The reaction was carried
out in 100 l of transcription buffer (40 mM Tris-HCl, 15 mM MgCl2, 5
mM dithiothreitol, and 0.5 mg/ml acetylated bovine serum albumin), 1
mM each of ATP, GTP, and UTP, and 24 M CTP, 250 Ci of [-32P]CTP,
40 units of RNase inhibitor, and 25 g of DNA. The reaction was started
with 1.4 g of T7 RNA polymerase. The reaction was incubated at 42 °C
for 2 h and another 0.56 g of enzyme was added and incubated for
another 2 h. RNase-free DNase (1 l) was added and the RNA was
purified using a RNeasyTM kit (Qiagen). Purity was determined by
urea-PAGE and the RNA concentration was determined by A260. Bind-
ing of trp t RNA was carried out in binding buffer (40 mM Tris-HCl, pH
8.0, 25 mM KCl, 10 mM MgCl2, 0.1 mM dithiothreitol, and 0.1 mM
EDTA). Binding reaction was started by adding labeled trp t RNA to a
final concentration of 1.2 nM to Rho varying from 0 to 12 nM (hexamer)
and incubating at 25 °C for 10 min, followed by filtration of the binding
reaction through an S&S nitrocellulose filter presoaked in 1 binding
buffer with 0.1 mg/ml denatured yeast RNA. The filter was washed
twice with 0.5 ml of binding buffer, dried briefly, and measured with a
scintillation counter (6). The percent of Rho binding RNA was measured
at saturating RNA concentrations from the moles of RNA bound to Rho
times the binding efficiency of Rho to the filter (24) using published
procedures (23) and used to estimate the concentration of binding-
active Rho. The L50 value, the concentration of Rho that gives half-
maximal retention of trp t RNA was measured using the binding-active
Rho concentrations. The Knd and the nth root of Knd was measured as
described (24).
Fluorescence Measurements—The fluorescence of F355W and wild-
type Rho was determined using a Cary Eclipse spectrofluorimeter at
100 nM Rho monomer in 40 mM Tris-HCl, pH 7.9, 50 mM KCl, 12 mM
MgCl2, 0.1 mM EDTA, and 0.1 mM dithiothreitol. Emission spectra were
recorded between 300 and 450 nm by excitation at 280 nm, and the
spectra were compared by zeroing at 300 nm.
RESULTS
Studies of RNA-protein interactions show that base stacking,
geometric complementarity, and coulombic forces contribute to
binding (25, 26). A model defining the Rho secondary RNA-
binding/RNA-tracking site was proposed based on the symme-
try of Rho subunits and the identification of conserved arginine
and lysine residues located on the surface of the central hole of
the hexameric Rho assembly (18). The notion that RNA track-
ing occurred through the central hole of Rho was based on RNA
cross-linking experiments (17) and by homology to known
helicases (27). A technique referred to alanine scanning, which
converts selected residues to alanine (glycine), was applied to
conserved arginine and lysine residues in the central hole of
Rho. The loss of positively charged amino acid residues on Rho
function was assessed by comparing the kinetic properties of
the mutated Rho protein with wild-type. We included an addi-
tional Rho mutant, F355W, in our study to further verify the
Rho model. Residue Phe355 was homologous to Tyr331 in E.
coli F1-ATP synthase. Residue Tyr
331 has been implicated in
ATP binding (28) and was base stacked with the adenosine
moiety of ATP (29). Accordingly, the replacement of the phe-
nylalanine 355 moiety in Rho with tryptophan provides a
potential fluorescence probe sensitive to ATP binding.
Generation of Rho Mutants—The plasmid pET-RhoW (19),
which expresses wild-type Rho with a N-terminal His tag using
a pET14b vector with a T7 RNA polymerase system, was used
as a template for introducing site mutations. Table I summa-
rizes the residues changed and the effect change had on mutant
protein expression in various expression systems. The mutant
proteins were first expressed from pET14b in the hosts
BL21(DE3)pLysS or BL21SI (salt-induced host). Of the 15 mu-
tants in which positively charged amino acids were replaced,
only R212G, R347G, K348A, and wild-type grew in the salt-
induced host expression strain. The induction of R347G
and K348A with isopropyl-1-thio--D-galactopyranoside in
BL21(DE3)pLysS caused a pronounced decrease in the growth
of the cells. This observation suggested that these specific Rho
mutations had a negative effect on cell growth. The remaining
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mutations, when introduced into the BL21 strains, generated
few, if any, transformants and those that grew produced trun-
cated protein although the plasmid was stable in host JM109
(data not shown).
Expression from the pBAD33 vector under the arabinose
promoter was generally under tighter control (21). The XbaI-
HindIII fragment containing the entire rho gene from the
pET14b was placed in pBAD33, transformed into host
MG1655, and expression was induced by adding 0.2% arabi-
nose. Expression of K352A, K298A, and R299A were obtained
using the pBAD33 vector. The remaining mutants either did
not grow when pBAD33 was transformed into MG1655 or did
not express protein. Transforming vectors into the  host strain
HSM174, which lacked T7 RNA polymerase, and inducing ex-
pression with  phage CE6 accomplished expression of the
remaining mutant proteins from pET14b vectors R160A,
R238A, R269A, R272A, K283E, R296A, R353A, and R384A.
Individual colonies were grown in LB media containing 0.2%
maltose and ampicillin to 0.6–1.0 A600. Expression was induced
by the addition of 2–4  109 plaque-forming units ml1  phage
CE6 containing the gene for the T7 RNA polymerase. Three h
after infection, cells were harvested, lysed, and Rho-purified
using the HiTrap metal chelating column bound with Ni2.
These mutants overexpressed protein; however, R160A,
R269A, and K283E exhibited no poly(C)-dependent ATPase
activity and R272A and R384A produced inclusion bodies that
could not be solubilized.
Poly(C)-dependent ATP Hydrolysis Activity—The poly(C)-de-
pendent ATPase activity for the Rho mutants was measured as
a function of ATP concentrations (Table II). All of the mutant
proteins exhibited a decrease in kcat for ATP hydrolysis when
compared with wild-type. Wild-type kcat was 2380 min
1, and
only R296A approached this value at 2000 min1. The other
mutants showed kcat values one-half or less of wild-type. Three
mutants (R160A, R269A, and K283E) were partially soluble
but had no ATP hydrolysis activity. The Km for His-tagged
wild-type was 5-fold higher than we reported for wild-type
Rho (20). This value was consistently observed throughout
these experiments. Wild-type Rho exhibited a Km(ATP) of 57 M,
whereas the remaining mutants had either similar (R296A,
R299A, K352A, and R353A) or lower (R212G, R347G, and
K348A) Km values ranging from 14 to 36 M, except for K336A,
which gave a Km(ATP) of 125 M. With the exception of R296A
and K336A, amino acid changes at these positions did not
adversely affect ATP binding but substantially affected ATP
hydrolysis.
The mutations R347G, K348A, K352A, R353A, and F355W
were clustered on or near the H-helix close to the adenosine-
binding site for ATP. Mutations R347G, K348A, K352A, and
R353A showed a 50–90% loss in kcat for poly(C)-dependent ATP
hydrolysis, whereas the Km for ATP was similar to or lower
than wild-type.
Poly(dC)-Ribo(C)10-stimulated ATP Hydrolysis—ATP hy-
drolysis rates are induced by binding RNA at the secondary
binding/tracking site (3, 19, 30). Amino acid substitutions that
alter RNA binding at the secondary/tracking site were expected
to alter the kinetics of ATP hydrolysis. RNA activation of ATP
hydrolysis activity was determined by varying the ribo(C)10
concentrations in the presence of saturating concentrations of
poly(dC) and ATP. Most mutant proteins exhibited decreased
kcat values compared with the wild-type value of 850 min
1
(Table II), and the decrease in the kcat for ribo(C)10 activation
generally mirrored the kcat values determined in the poly(C)-
dependent ATPase assay. Of significance, R296A, K348A,
and K352A showed kcat values similar with wild-type. The
Km(ribo(C)10) values were sensitive to alanine screening. The
Km(ribo(C)10) for wild-type Rho was 9.0 M. The K336A muta-
tion showed no detectable poly(dC)-ribo(C)10-stimulated ATP
hydrolysis activity, and the poly(C)-dependent ATPase activity
was diminished nearly 18-fold. This was the only mutation
with a large increase in the Km(ATP), suggesting that Lys
336 has
a direct role in ATP binding. This finding supports the notion
that residues from neighboring subunits can influence ATP
binding across the subunit interface (31).
By comparison, most of the active mutants exhibited
Km(ribo(C)10) values 5–100-fold greater than wild-type
Rho, with the only exception being R347G, which had a
Km(ribo(C)10) value of 5.6 M. R296A and K352A stand out as
unusual, the kcat for poly(dC)-ribo(C)10-dependent ATP hydrol-
ysis exceeded that of wild-type yet the Km for ribo(C)10 was 500
and 1000 M, respectively, which was 50–100-fold greater than
wild-type Rho. A large increase in the Km(ribo(C)10) coupled
with a slight increase in kcat for ATP hydrolysis suggest that
the on-rate for ribo(C)10 was lower. To support this notion
transcription termination efficiencies should be considerably
less for these mutants than for wild-type.
Transcription Termination—In vitro transcription termina-
tion reactions were measured using the modified trp operon
fragment (22), as reported (6). Fig. 1A shows the transcription
termination reactions of wild-type Rho, R212G, R296A, K298A,
and R299A, which are located at the putative N-terminal locus
of the RNA tracking site. Lane 12 shows the run-off transcript
(labeled A in Fig. 1A) in the absence of Rho; lane 1 shows the
transcripts in the absence of Rho but with the inclusion of 28
TABLE I
Summary of mutations and protein expression
Rho Locus Base change Expression system Activity
Wild-type pET14b-BL21pLysS 
R160A C-terminal CGC to GCC pET14b-CE6-HMS174 
R212G N-terminal CGT to GGT pET14b-BL21pLysS 
R238A N-terminal CGC to GCC pET14b-CE6-HMS174 
R269A N-terminal CGT to GCT pET14b-CE6-HMS174 
R272A N-terminal CGC to GCC pET14b-CE6-HMS174 a
K283E N-terminal CGC to GCC pET14b-CE6-HMS174 
R296A N-terminal CGT to GCT pET14b-CE6-HMS174 
K298A N-terminal AAA to GCA pBAD33-MG1655 
R299A N-terminal CGC to GCC pBAD33-MG1655 
K336A N-terminal AAA to GCA pBAD33-MG1655 
R347G C-terminal CGT to GGT pET14b-BL21pLysS 
K348A C-terminal AAG to GCG pET14b-BL21SI 
K352A C-terminal AAA to GCA pBAD33-MG1655 
R353A C-terminal CGC to GCC pET14b-CE6-HMS174 
R384A C-terminal CGC to GCC pET14b-CE6-HMS174 a
F355W C-terminal TTC to TGG pET14b-BL21SI 
a Expression resulted in the formation of insoluble inclusion bodies.
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M rifampicin, lane 2 shows transcript produced in the pres-
ence of wild-type Rho, and lane 3 shows the effect of 50 M
bicyclomycin on wild-type Rho. Transcription termination effi-
ciencies as a percentage of wild-type Rho for the mutant pro-
teins as depicted in Fig. 1, A and B, are summarized in Table II.
Mutant R212G generated only 14% of the terminated tran-
scripts compared with wild-type Rho, whereas mutants R296A,
K298A, and R299A generated 53, 32, and 23% terminated
transcripts, respectively. The terminated transcripts for the
mutants were longer than those seen for wild-type Rho. The
terminated transcripts are labeled 1, 2, and 3 in Fig. 1A.
Wild-type Rho produced terminated transcripts dominated by 2
and 3 with a small amount of 1. The mutant Rho proteins
predominantly produced the longer terminated transcripts 1
and 2 but little, if any 3, the shortest terminated transcript.
The production of longer terminated transcripts was reminis-
cent of the intermediate-size transcripts seen in the titration of
Rho with the antibiotic bicyclomycin (6) and the transcripts
generated from bicyclomycin-resistant Rho mutants (6). We
previously concluded that bicyclomycin slowed the 5 to 3
translocation of Rho down the RNA, allowing the RNA polym-
erase to proceed further along the DNA before transcription
termination. A similar argument can be made for the effects of
amino acid substitution on transcription termination.
Fig. 1B shows transcription termination from mutations
(R347G, K348A, K352A, and R353A) clustered on the C-termi-
nal RNA tracking locus. Mutants R347G, K348A, and K352A
generated 50% or less terminated transcripts than wild-type,
and the terminated transcripts were longer. The mutant
R353A showed 97% transcription termination efficiency and
gave predominantly larger terminated transcripts than seen
for wild-type Rho. This mutant was of interest because the kcat
for ATP hydrolysis was between one-third and one-fourth that
of wild-type but transcription termination efficiency was not
affected. The rate of ATP hydrolysis did not correlate well with
transcription termination efficiency. We found a better corre-
lation between the termination efficiency and the Km(ribo(C)10)
value in the poly(dC)-ribo(C)10 assay. Bicyclomycin effectively
inhibited mutant Rho proteins as seen in Fig. 1. Also, the
kinetics of Rho inhibition by bicyclomycin was measured as a
function of ATP concentrations using the poly(C)-dependent
ATPase assay and we observed that the Ki for bicyclomycin was
not altered (data not shown).
RNA Binding Experiments—The binding of trp t RNA to
Rho mutants was measured to determine whether amino acid
substitutions at putative secondary RNA-binding/tracking
sites affected RNA binding at the primary site. Fig. 2 shows the
binding curves and the percent Rho binding RNA for several
mutants and the data is summarized in Table III. The filter
binding efficiency (23) for wild-type Rho was determined to be
very close to unity. Because of the complexity of the binding,
the data was analyzed by three separate methods. The simplest
was the L50 value, which was the concentration of Rho that
gives half-maximal retention of trp t RNA. Several mutants
showed sigmoidal behavior upon RNA binding, and the Hill
constants for sigmoidal binding (determined from the slope of
the Hill plot at the corresponding L50 value) varied between
1.9 and 4.4 similar to that reported (28). The Knd values were
calculated using Equation 2 from Ref. 24 and the Hill constants
were as described in Table III. Finally, the nth root of Knd was
determined. Wild-type Rho showed the tightest binding with a
L50 of binding occurring at 0.81  0.03 nM, whereas the weak-
est binding mutant, K298A, showed a L50 of 9.0 nM. The L50
values for the other mutants fell within a range of 1.8 to 3.6 nM.
Binding of trp t to R296A, K298A, R353A, and K348A showed
binding efficiencies near 50%. Data presented in Table III
suggested that mutations distant from the known primary
binding site influence tight RNA binding only slightly but may
have weakened the hexamer formation in the absence of RNA.
Fluorescence—Fig. 3 shows the fluorescence emission spec-
tra of F355W and wild-type Rho in the absence and presence of
100 M ATP. We observed that in proceeding from wild-type to
F355W, the emission maximum shifted from 375 to 350 nm and
increased in emission intensity in the absence of ATP. This
emission intensity increase was because of the additional tryp-
tophan residue in the F355W mutant, an increase from one to
two tryptophan residues. The blue shift suggests that the ad-
ditional tryptophan residue was in a solvent inaccessible loca-
tion in Rho consistent with its predicted placement. The addi-
tion of 100 M ATP caused a 74% decrease in the fluorescence
intensity of F355W at 350 nm. By comparison, less than 10% of
the fluorescence intensity of wild-type Rho was quenched at
350 nm upon ATP (100 M) addition. These data provided
strong evidence that Phe355 is close to the adenosine-binding
site, in agreement with the generated structural model for Rho
based on the crystal structure of F1-ATP synthase (32). The
relative amount of fluorescence quenching upon ATP addition
was greater than that seen for F1-ATP synthase, presumably
because F355W Rho has only one other tryptophan residue.
DISCUSSION
The secondary RNA-binding/tracking site is poorly defined,
and only a few mutations with phenotypes consistent with
defects in tracking have been identified. Mutations (K352E
(30), M327T (33), and E342G (33)) altering ribo(C)10 binding to
Rho have been isolated. Many mutants have decreased kcat for
ATP as measured by poly(C)-stimulated ATP hydrolysis. The
positions of these mutations are distant from the ATP hydrol-
ysis pocket and are scattered on the inside face of the hexamer
(33). We have proposed a structural model of Rho based on the
crystal structure of F1-ATP synthase (18) where the secondary
tracking site lies within the central hole, and have provided
TABLE II
Kinetic paramaters of mutant Rho proteins
Rho
Poly(C)-dependent ATPase Ribo(C10)-dependent ATPase Termination
efficienciesKm(ATP) kcat Km(Ribo(C)10) kcat
M min1 M min1 %
Wild-type 57 2380 9 850 100
R212G 15 266 333 435 14
R238A 25 167 410 37
R296A 54 2000 500 1110 53
K298A 36 444 54 100 32
R299A 57 833 333 154 23
K336A 125 133 0
R347G 14 208 5.6 161 41
K348A 14 222 286 800 30
K352A 54 1000 1000 1000 50
R353A 42 588 12 312 97
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experimental data to support this hypothesis (34). Moreover,
we have identified positively charged amino acids on the inside
face of the central hole that can be subdivided into two separate
loci.
Enzymatic Activities—Three enzymatic activities helped
characterize the mutant and wild-type Rho proteins. Poly(C)-
dependent ATP hydrolysis measured the ability of poly(C) to
activate Rho-dependent ATP hydrolysis. Poly(C) binds strongly
to both the primary and secondary binding sites providing
maximum ATP hydrolysis rates. In this assay, the ATP con-
centrations were varied, whereas poly(C) was maintained at
saturating levels. The Km(ATP) value was usually insensitive to
parameters affecting RNA binding, whereas the kcat for ATP
hydrolysis reflected activation by RNA binding at the tracking
site. Because poly(C) binds tightly to both primary and second-
ary binding sites, this assay is not an effective measure of
Rho-RNA interactions necessary for Rho translocation. RNA
binding interactions at the tracking site can be determined by
measuring the poly(dC)-ribo(C)10-dependent ATP hydrolysis
activity as a function of ribo(C)10 concentration. Both kcat for
ATP hydrolysis and Km(ribo(C)10) are indicators of altered RNA
binding at the tracking site. Transcription termination is the
most sensitive indicator of overall Rho function, exceeding ATP
hydrolysis activity. For example, the inhibitor, bicyclomycin,
has an I50 value for poly(C)-dependent ATP hydrolysis of 60 M,
whereas the transcription termination I50 value for bicyclomy-
cin was 5 M (19). Anti-termination was achieved by slowing
the tracking rate such that Rho cannot catch the RNA polym-
erase, and under these conditions ATP hydrolysis may only be
marginally affected. This kinetic coupling model suggests that
small changes in ATP hydrolysis may not be responsible for
large increases in anti-termination.
Trp t RNA Binding—The trp t RNA binding measured
whether the selected mutations adversely altered recognition
at the rut (primary binding) site contributing to the dominant-
negative behavior during mutant protein overexpression. The
dominant-negative effect can be reasoned as mutant Rho com-
peting with background wild-type for rut sequences. The L50 or
nth root of Knd for trp t binding was not significantly altered by
these mutations (Table III). This data suggests that rut site
recognition was not an important factor in the phenotype of the
FIG. 1. A, transcription termination mediated by Rho mutants clus-
tered in the N-terminal locus of the proposed tracking site. Lane 1,
reaction carried out in the presence of 28 M rifampicin without Rho or
bicyclomycin; lane 2, transcription termination carried out in the pres-
ence of 70 nM Rho hexamer; lane 3, transcription termination carried
out in the presence of 70 nM Rho hexamer in the presence of 50 M
bicyclomycin. Lanes 4, 6, 8, and 10, transcription termination carried
out in the presence of 70 nM R212G, R296A, K298A, and R299A mutant
Rho hexamers, respectively, without bicyclomycin, and lanes 5, 7, 9, and
11, transcription termination carried out in the presence of 70 nM
R212G, R296A, K298A, and R299A mutant Rho hexamers, respectively,
in the presence of 50 M bicyclomycin. Lane 12, transcription termina-
tion reaction in the absence of Rho without rifampicin and bicyclomycin.
The transcript labeled A is the run-off transcript; transcripts 1, 2, and
3 are progressively shorter terminated transcripts. The more efficient
Rho is the shorter the transcripts. B, transcription termination medi-
ated by Rho mutants clustered in the C-terminal locus of the proposed
tracking site. Lane 1, transcription termination carried out in the
presence of 70 nM Rho hexamer; lane 2, transcription termination
carried out in the presence of 70 nM Rho hexamer in the presence of 50
M bicyclomycin. Lanes 3, 5, 7, and 9, transcription termination carried
out in the presence of 70 nM R347G, K348A, K352A, and R353A mutant
Rho hexamers, respectively, without bicyclomycin, and lanes 4, 6, 8, and
10, transcription termination carried out in the presence of 70 nM
R347G, K348A, K352A, and R353A mutant Rho hexamers, respectively,
in the presence of 50 M bicyclomycin. The transcript labeled A is the
run-off transcript, whereas transcripts 1, 2, and 3 are progressively
shorter terminated transcripts. Lane 11, transcription termination re-
action in the absence of Rho and bicyclomycin.
FIG. 2. Trp t RNA binding to mutant Rho proteins. Binding of
trp t RNA at the primary RNA recognition site was compared among
the mutant Rho proteins with mutations affecting RNA binding at the
RNA-tracking site. All samples contained 1.2 nM 32P-labeled trp t RNA
and the indicated concentrations of Rho (hexamer) in the absence of
adenosine nucleotides, wild-type Rho (), R296A (E), K298A (),
K352A (ƒ), R353A (f), F355W (), R212G (), R347G (), and
K348A (Œ).
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mutation. These binding experiments were done in the absence
of adenosine nucleotides, which are reported to increase RNA
binding affinity to Rho (24). However, decreased total RNA
binding (percent Rho binding RNA) was seen for several mu-
tants raising the possibility that hexamer formation was weak-
ened in the absence of RNA. R296A showed 50% less trp t RNA
binding, however, this mutant also showed a higher kcat for
poly(C)-dependent ATP hydrolysis than wild-type. This sug-
gests that hydrolysis activity was insensitive to small differ-
ences in the L50 for trp t binding. Whereas trp t binding was
a measure of the primary RNA binding affinity, the Km for
ribo(C)10 was a better measure of RNA binding to the second-
ary site. Most of the mutants were defective in transcription
termination and displayed large increases in the Km for
ribo(C)10. These findings suggested that the mutations were
acting at the secondary RNA-binding site primarily and the
dominant negative phenotype arose from the slower tracking
rates (poorer RNA binding at the secondary RNA-binding site)
in the mutant Rho proteins rather than the initial binding step
of mutant Rho protein to the rut sequences. Slower tracking
results in decreased termination and ultimately in cell death.
The Model—Fig. 4 shows a dimeric model of Rho based upon
the crystal structure of an  and  subunit pair of F1-ATP
synthase (29) threaded to the Rho sequence and energy mini-
mized as described (18) and shows only residues 151–419 in-
cluding the ATP binding and hydrolysis pocket; the primary
RNA recognition domain, residues 1–150, has been removed.
Because the selected mutations can affect Rho at two distinct
secondary RNA-binding sites on Rho, we have divided the
individual mutants into two groups. We define top as residues
next to the N-terminal RNA recognition domain, residues
151–340. The ATP hydrolysis pocket is part of this subdomain
including the P-loop residues 181–187 (12) and includes the
bicyclomycin binding pocket defined by mutations affecting
antibiotic binding (35), residues 219, 266 (5), 210 (8), 208, and
337 (18). The C-terminal or bottom locus, residues 341–419,
was located below the ATP hydrolysis domain and contains the
adenosine-binding pocket (Fig. 5). Both loci contain positively
charged residues, which when altered influence the RNA track-
ing ability of Rho. The fluorescence quenching of tryptophan
emission by ATP (Fig. 3) supports this structural arrangement
and our assignment of the ATP-binding domain.
The Top or N-terminal Locus—Residues Arg212, Arg238,
Arg269, Arg272, Lys283, Arg296, Lys298, Arg299, and Lys336 are
found in the N-terminal locus pointing toward the central hole
of Rho. Mutations in three of these residues resulted in inactive
Rho: R272A formed insoluble inclusion bodies; R269A and
K283E were isolated, purified, and shown to have no poly(C)-
stimulated ATP hydrolysis activity. Lysine 283 on the Q-loop
was also shown to be important in Rho ATP hydrolysis activity
(36). R238A, R296A, K298A, and R299A displayed dominant-
negative growth suggesting competition with the host wild-
type Rho but preventing effective termination. We found that
most of the mutant proteins had altered kinetic properties
(Km(ATP) and kcat) in the poly(C)-dependent ATPase assay com-
TABLE III
Trp t RNA binding to mutant Rho proteins
L50 is the concentration of Rho that gives half-maximal retention of trp tRNA, the Knd values were derived from Equation 2 (
24), fR(e[L]n)/
(Knd[L]n).




Wild-type 0.81  0.03 100 1.21  0.14 1.0 1.20  0.15
R296A 3.56  0.24 50 5.49  0.31 1.9 2.57  0.34
K298A 9.11  0.13 46 81.12  6.17 2.7 5.12  0.07
K352A 1.83  0.01 90 5.92  0.1 2.5 2.09  0.14
R353A 2.94  0.16 44 5.50  1.2 4.1 1.52  0.12
R212G 3.44  0.26 90 48.7  13.8 2.6 4.46  0.17
R347G 2.46  0.30 60 13.79  4.2 4.4 1.84  0.23
K348A 1.86  0.01 44 1.24  0.03 3.7 1.07  0.02
F355W 1.93  0.11 87 7.94  0.65 3.0 2.02  0.08
aKd is the nth root of Knd.
FIG. 3. Fluorescence emission spectra of wild-type and F355W
Rho proteins. Rho concentrations were 100 nM, and the spectra were
recorded using an excitation wavelength of 280 nm in the absence and
presence of 100 M ATP.
FIG. 4. A dimeric model of Rho based upon the crystal struc-
ture of an  and  subunit pair of F1-ATP synthase (29) threaded
to the Rho sequence and energy minimized as described (18).
This figure shows only residues 151–419 including the ATP binding and
hydrolysis pocket; the primary RNA recognition domain, residues
1–150, has been removed. Outlined in black boxes are two putative
secondary RNA (tracking) loci facing the central hole or Rho; positively
charged residues altered by site mutations are identified in blue and
placed in a rectangle box. The green subunit is depicted as binding ATP
(red), whereas the yellow strand is depicted as not binding ATP.
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pared with wild-type Rho. The only exception was R296A,
which showed comparable Km(ATP) and kcat values with wild-
type Rho. K298A and K299A had kcat of 19 and 35% of wild-
type, respectively, whereas the Km(ATP) values were similar to
wild-type. R212G and K336A were adjacent to the ATP hydrol-
ysis pocket and showed a large decrease in the turnover num-
ber (kcat), 11 and 6%, respectively, compared with wild-type
Rho. The Km(ATP) for R212G was lower than wild-type, but the
Km(ATP) for K336A was more than double the native enzyme.
Poly(dC)-ribo(C)10-stimulated ATPase activity for R296A
(Km  500 M) showed a Km(ribo(C)10) more than 50-fold
greater than wild-type (Km  9 M), indicating that RNA bind-
ing at the secondary site in R296A was weaker than wild-type.
Interestingly, there was an increase in the ATP turnover for
this mutant from 850 to 1110 min1. The other N-terminal
locus mutants showed elevated Km(ribo(C)10) values ranging
from 54 to 410 M and decreased kcat values ranging from 435
to 37 min1 (Table II). R212G showed a large decrease in
turnover for poly(C)-dependent ATPase activity, exceeding the
decrease in the turnover number for poly(dC)-ribo(C)10 depen-
dent activity. The activity for K336A in the poly(dC)-ribo(C)10
dependent assay could not be measured.
Transcription termination was often impaired in mutants
that had altered ribo(C)10 binding (Table II). R296A acted as
a classic uncoupler, where uncoupling was defined as the
absence of detectable translocation without the loss of ATP
hydrolysis. ATP hydrolysis provides the energy for RNA
translocation, and R296A impaired both translocation and
transcription termination without interfering with ATP hydrol-
ysis. The rate-limiting step in Rho function is presumably
translocation (37), and if this step is circumvented or uncou-
pled, an increase in ATP hydrolysis could be expected, similar
to the increase in electron transport rates when ATP synthesis
is uncoupled from electron transport.
As anticipated, the transcription termination efficiencies
were affected by the other N-terminal locus mutations (Table
II). Most of these mutants showed large decreases in the kcat for
ATP hydrolysis, increased Km(ribo(C)10) values, and decreased
transcription termination efficiencies. We suggest that amino
acid substitution in these mutant Rho proteins disrupted RNA
binding at the tracking site and prevented the formation of the
catalytically active conformation necessary for ATP hydrolysis.
The loss of RNA binding at the N-terminal locus resulted in
greatly diminished ATP hydrolysis and greatly reduced tran-
scription termination. Again, R296A is phenotypically differ-
ent; ATP hydrolysis increased but transcription termination
decreased. This finding suggests that in R296A RNA binding is
sufficient to promote ATP hydrolysis, but is not tight enough to
prevent RNA slippage. The net result is that translocation is
ineffective or does not occur and thereby circumvents the rate-
determining step. We predict that R296A may show an altered
initial presteady-state rate of ATP hydrolysis compared with
wild-type Rho (37, 38).
The Bottom or C-terminal Locus—Residues R347G, K348A,
K352A, R353A, and R384A in the C-terminal locus, speculated
to be involved in Rho-RNA tracking, were selected for study.
R347G, K348A, K352A, and R353A are believed to reside in the
putative H-helix, which on one face is projected to bind to the
adenosine ring of ATP and on the other face to RNA. Fig. 5
shows the positions of these residues in relation to the ATP
binding. Two other residues, Lys402 and Lys407, were consid-
ered promising but were not pursued. Completing our muta-
tional studies for this locus was F355W, which positioned a
tryptophan residue near the ATP binding pocket.
R384A and R160A were only expressed as inactive inclusion
bodies. Moreover, these inclusion bodies were only generated in
the phage-induced expression system, and transformed cells
carrying this mutant in the other expression systems failed to
grow. The observed dominant-negative phenotype for these
mutants suggested a role in RNA tracking.
Mutants R347G, K348A, K352A, and R353A fell into two
types, those with Km(ribo(C)10) values similar to wild-type Rho
and those with Km(ribo(C)10) values 20–100 times higher.
R347G and R353A had similar Km(ribo(C)10) values to wild-
type, but their Km(ATP) values were lower than those of native
enzyme. The kcat for ATP hydrolysis for R347G and R353A was
9 and 25% of wild-type in the poly(C)-dependent ATPase assay
and 19 and 37% for the poly(dC)-ribo(C)10-mediated ATPase
assay. Transcription termination for R347G was only 41% of
wild-type Rho and produced only the largest terminated tran-
script, whereas R353A activity was almost identical to wild-
type Rho and showed only minor differences in the termination
pattern (Fig. 1B). R353A showed a 3.6-fold increase in the L50
for trp t RNA binding and only 44% of this Rho bound RNA,
but this mutant still effectively terminated transcription and
did not have an altered Km for ribo(C)10.
Mutants K348A and K352A showed increased Km(ribo(C)10)
values compared with wild-type Rho (Km(ribo(C)10)  9 M) at
286 and 1000 M, respectively. K348A showed a defective kcat
for ATP hydrolysis, a decreased Km(ATP) value, and a transcrip-
tion termination efficiency that was 30% of wild-type. Again,
there was a strong correlation between Km(ribo(C)10) and tran-
scription termination efficiency. We found that the kcat for
poly(dC)-ribo(C)10-dependent ATP hydrolysis was greater than
wild-type Rho and that this mutant displayed an overall pat-
tern of inhibition comparable with R296A, showing decreased
transcription termination efficiency but increased ATP hydrol-
ysis, which suggests that K352A behaves as an uncoupler.
The E. coli F1-ATP synthase  subunit counterpart of Phe
355,
Tyr331 (28), is base stacked with the adenosine and the tryp-
tophan mutant Y331W shows fluorescence quenching upon
ATP binding (32, 28). The Rho F355W mutation decreased the
kcat for poly(C)-dependent ATP hydrolysis by only 50%,
whereas Km(ATP) increased from 57 to 83 M. Furthermore,
transcription termination was not affected by this amino acid
substitution. Fig. 3 shows a blue shift in fluorescence emission
maximum from 380 to 350 nm and an increase in total fluores-
cence compared with wild-type Rho. A large decrease in fluo-
rescence was observed for the F355W mutant upon the addition
of 100 M ATP but not for wild-type. These data suggested that
Rho Phe355, like F1-ATP synthase Tyr
331, interacts strongly
with ATP.
Fig. 5 shows the orientation of amino acids Arg347, Lys348,
FIG. 5. A structural model of residues on the putative H-helix
based on the structure of F1-ATP synthase  subunit, where
Phe355 interacts with the adenosine ring of ATP on one face of
the helix and residues Arg347, Lys348, Lys352, and Arg353 interact
on the other face, presumably binding RNA.
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Lys352, Arg353, and Phe355 with respect to ATP binding. Lys348
and Lys352 point out of the opposite face of the helix from
Phe355, which binds ATP. Losses of positive charges at these
residues caused a large increase in the Km(ribo(C)10) for RNA
binding at the tracking site. We found that the Km(ATP) for
Lys348 was smaller than wild-type Rho, suggesting that RNA
binding at the C-terminal locus may alter ATP binding. Muta-
tions introduced at Arg347 and Arg353 did not greatly affect the
L50 for trp t RNA binding and are positioned away from the
putative RNA binding face of the H-helix. Arg347 is close to
the  phosphate of ATP, consistent with the large decreases in
the kcat for ATP hydrolysis observed for R347G in the poly(C)-
dependent and the poly(dC)-ribo(C)10-dependent ATPase
assays.
Our model (18) involves alternate binding and release of
RNA at two loci in Rho catalyzed by ATP binding, hydrolysis,
and ADP release in a sequential mechanism and our data, on
the effect site mutations on RNA binding to the tracking site is
consistent with this model. Studies are in progress that mea-
sure ATP binding to Rho using F355W fluorescence quenching
under different ligand binding conditions and the use of double
mutants geared to detect alternating RNA and ATP binding.
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